

**Supplemental data**


**List of contents:**

|   |    |
|---|----|
| eFigure 1. Risk of bias summary about risk of bias assessment for each included trial                   | 2  |
| eFigure 2. Funnel plot to assess publication bias for effect of SGs on FBG .....                        | 3  |
| eFigure 3. Funnel plot to assess publication bias for effect of SGs on HbA1c .....                      | 4  |
| eFigure 4. Begg's rank correlation to assess publication bias for effect of SGs on FBG                  | 5  |
| eFigure 5. Begg's rank correlation to assess publication bias for effect of SGs on HbA1c.....           | 6  |
| eFigure 6. Egger's regression tests to assess publication bias for effect of SGs on FBG                 | 7  |
| eFigure 7. Egger's regression tests to assess publication bias for effect of SGs on HbA1c.....          | 8  |
| eFigure 8. Plots of leave-one-out sensitivity analyses for effect of SGs on FBG (A) and HbA1c (B) ..... | 9  |
| eTable 1. Detailed search strategies used for the database search.....                                  | 10 |
| eTable 2. Summary of findings for effect of SGs on glucose metabolism.....                              | 12 |
| List of excluded studies .....  | 14 |


**eFigure 1.** Risk of bias summary about risk of bias assessment for each included trial

|                    | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|--------------------|---|---|---|---|--|--------------------------------------|------------|
| Ajami 2020         | ?   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Aswathiah 2022     | ?   | ?                                       | -   | ?   | +  | +                                    | +          |
| Barriocanal 2008   | ?   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Chan 2000          | ?   | ?                                       | +   | ?   | +  | ?                                    | +          |
| da Silva 2006      | ?   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Ferri 2006         | +   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Hsieh 2003         | +   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Maki 2008          | ?   | ?                                       | +   | ?   | +  | ?                                    | +          |
| Simoens 2022       | +   | ?                                       | -   | ?   | +  | -                                    | +          |
| Stamataki 2020     | +   | ?                                       | -   | ?   | +  | +                                    | +          |
| Tanzidi-Roodi 2023 | +   | +                                       | +   | +   | +  | +                                    | +          |
| Villano 2021       | +   | ?                                       | +   | +   | +  | -                                    | +          |


**eFigure 2.** Funnel plot to assess publication bias for effect of SGs on FBG




**eFigure 3.** Funnel plot to assess publication bias for effect of SGs on HbA1c




**eFigure 4.** Begg's rank correlation to assess publication bias for effect of SGs on FBG




**eFigure 5.** Begg's rank correlation to assess publication bias for effect of SGs on HbA1c




**eFigure 6.** Egger's regression tests to assess publication bias for effect of SGs on FBG



**eFigure 7.** Egger's regression tests to assess publication bias for effect of SGs on HbA1c



**eFigure 8.** Plots of leave-one-out sensitivity analyses for effect of SGs on FBG (A) and HbA1c (B)



**eTable 1.** Detailed search strategies used for the database search

| Pubmed |  |                |
|--------|--|----------------|
| Step   | Detailed Search strategies                   | No. of records |
| #1     | "Stevia"[Mesh]                               | 622            |
| #2     | Stevia*[Title/Abstract]                      | 1,133          |
| #3     | "steviol" [Supplementary Concept]            | 235            |
| #4     | "stevioside" [Supplementary Concept]         | 463            |
| #5     | "rebaudioside A" [Supplementary Concept]     | 171            |
| #6     | Sweetleaf*[Title/Abstract]                   | 8              |
| #7     | "Eupatorium rebaudianum*"[Title/Abstract]    | 1              |
| #8     | "steviol glycoside*"[Title/Abstract]         | 477            |
| #9     | "Diabetes Mellitus"[Mesh]                    | 512,937        |
| #10    | "Blood Glucose"[Mesh]                        | 184,070        |
| #11    | "blood sugar*"[Title/Abstract]               | 17,145         |
| #12    | "Blood Glucose"[Title/Abstract]              | 88,016         |
| #13    | "Diabetes Mellitus"[Title/Abstract]          | 261,722        |
| #14    | "Insulin"[Mesh]                              | 200,036        |
| #15    | Insulin[Title/Abstract]                      | 410,515        |
| #16    | "Glucose Metabolism Disorders"[Mesh]         | 548,062        |
| #17    | Glucose Metabolism[Title/Abstract]           | 45,099         |
| #18    | Glucose Metabolic[Title/Abstract]            | 2,160          |
| #19    | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 | 1,508          |
| #20    | #9 OR #10 OR #11 OR #12 OR #13               | 726,894        |
| #21    | #14 OR #15 OR #16 OR #17 OR #18              | 817,530        |
| #22    | #20 OR #21                                   | 1,016,068      |
| #23    | #19 AND #22                                  | 193            |
| Embase |  |                |
| #1     | 'stevia'/exp                                 | 1,0591         |
| #2     | stevia*:ti,ab,kw                             | 1,148          |
| #3     | steviol:ti,ab,kw                             | 514            |
| #4     | stevioside:ti,ab,kw                          | 577            |
| #5     | 'rebaudioside a':ti,ab,kw                    | 308            |
| #6     | sweetleaf*:ti,ab,kw                          | 5              |
| #7     | 'eupatorium rebaudianum*':ti,ab,kw           | 0              |
| #8     | 'steviol glycoside*':ti,ab,kw                | 370            |
| #9     | 'diabetes mellitus'/exp                      | 1,119,858      |
| #10    | 'blood glucose'/exp                          | 286,648        |
| #11    | 'blood sugar*':ti,ab,kw                      | 1,898          |
| #12    | 'blood glucose':ti,ab,kw                     | 118,661        |
| #13    | 'diabetes mellitus':ti,ab,kw                 | 329,998        |
| #14    | 'insulin'/exp                                | 354,151        |
| #15    | insulin:ti,ab,kw                             | 497,269        |

|                       |   |           |
|-----------------------|---|-----------|
| #16                   | 'glucose metabolism disorders'/exp  | 1,351,100 |
| #17                   | 'glucose metabolism':ti,ab,kw   | 53,531    |
| #18                   | 'glucose metabolic':ti,ab,kw  | 2,545     |
| #19                   | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8  | 1,732     |
| #20                   | #9 OR #10 OR #11 OR #12 OR #13  | 1,283,317 |
| #21                   | #14 OR #15 OR #16 OR #17 OR #18   | 1,595,240 |
| #22                   | #20 OR #21  | 1,681,484 |
| #23                   | #19 AND #22   | 377       |
| <b>Web of Science</b> |   |           |
| #1                    | Stevia (topic) or Stevia* (topic) or steviol (topic) or stevioside (topic) or rebaudioside A (topic) or Sweetleaf* (topic) or Eupatorium rebaudianum* (topic) or steviol glycoside* (topic) | 3,875     |
| #2                    | Insulin (topic) or Glucose Metabolism Disorders (topic) or Glucose Metabolism (topic) or Glucose Metabolic (topic)  | 713,504   |
| #3                    | Diabetes Mellitus (topic) or Blood Mellitus (topic) or blood sugar* (topic) or Blood Glucose (topic)  | 506,677   |
| #4                    | #2 OR #3  | 1,006,297 |
| #5                    | #1 AND #4   | 394       |

**eTable 2.** Summary of findings for effect of SGs on glucose metabolism

| Outcomes                    | No. of participants<br>(studies) | Quality of the evidence    |                            | Anticipated absolute effects      |   |
|-----------------------------|----------------------------------|----------------------------|----------------------------|-----------------------------------|---|
|                             |                                  | Overall quality assessment | Assessment of each domain  | Risk with control group           | Risk difference with SGs <sup>1</sup> group             |
| FBG <sup>2</sup><br>(mg/dl) | 843 (11 studies)                 | ⊕⊕○○<br>Low <sup>3</sup>   | Risk of bias: high risk    | Ranging from -12.4<br>to 79 mg/dl | <b>MD 4.1 lower</b><br>(6.55 lower to 1.65<br>lower)    |
|                             |                                  |                            | Inconsistency: low risk    |                                   |   |
|                             |                                  |                            | Indirectness: low risk     |                                   |   |
|                             |                                  |                            | Imprecision: high risk     |                                   |   |
|                             |                                  |                            | Publication bias: low risk |                                   |   |
| HbA1c <sup>4</sup><br>(%)   | 336 (5 studies)                  | ⊕⊕○○<br>Low <sup>3</sup>   | Risk of bias: high risk    | Ranging from -0.1%<br>to 5.89%    | <b>MD 0.01 higher</b><br>(0.12 lower to 0.13<br>higher) |
|                             |                                  |                            | Inconsistency: low risk    |                                   |   |
|                             |                                  |                            | Indirectness: low risk     |                                   |   |
|                             |                                  |                            | Imprecision: high risk     |                                   |   |
|                             |                                  |                            | Publication bias: low risk |                                   |   |

**\*The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval; **MD:** Mean difference

### **GRADE Working Group grades of evidence**

**High quality:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate quality:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low quality:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low quality:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

<sup>1</sup> SGs: steviol glycosides;

<sup>2</sup> FBG: fasting blood glucose;

<sup>3</sup> High risks of bias and imprecision of study results;

<sup>4</sup> HbA1c: glycated hemoglobin

## List of excluded studies

1. V. Sambra, I. A. Vicuña, K. M. Priken, S. L. Luna, D. A. Allendes, P. M. Godoy, V. Novik and C. A. Vega, Acute responses of stevia and d-tagatose intake on metabolic parameters and appetite/satiety in insulin resistance, *Clin. Nutr. ESPEN*, 2022, **49**, 217-224.
2. S. Gregersen, P. B. Jeppesen, J. J. Holst and K. Hermansen, Antihyperglycemic effects of stevioside in type 2 diabetic subjects, *Metabolism*, 2004, **53**, 73-76.
3. C. Chupeerach, C. Yothakulsiri, R. Chamchan, U. Suttisansanee, K. Sranacharoenpong, A. Tungtrongchitr and N. On-Nom, The Effect of Coconut Jelly with Stevia as a Natural Sweetener on Blood Glucose, Insulin and C-Peptide Responses in Twelve Healthy Subjects, *Recent. Pat. Food Nutr. Agric.*, 2018, **9**, 127-133.
4. J. Ahmad, I. Khan, S. K. Johnson, I. Alam and Z. U. Din, Effect of Incorporating Stevia and Moringa in Cookies on Postprandial Glycemia, Appetite, Palatability, and Gastrointestinal Well-Being, *J. Am. Coll. Nutr.*, 2018, **37**, 133-139.
5. S. L. Tey, N. B. Salleh, J. Henry and C. G. Forde, Effects of aspartame-, monk fruit-, stevia- and sucrose-sweetened beverages on postprandial glucose, insulin and energy intake, *Int. J. Obes. (Lond.)*, 2017, **41**, 450-457.
6. S. L. Tey, N. B. Salleh, C. J. Henry and C. G. Forde, Effects of non-nutritive (artificial vs natural) sweeteners on 24-h glucose profiles, *Eur. J. Clin. Nutr.*, 2017, **71**, 1129-1132.
7. G. Farhat, V. Berset and L. Moore, Effects of Stevia Extract on Postprandial Glucose Response, Satiety and Energy Intake: A Three-Arm Crossover Trial, *Nutrients*, 2019, **11**.
8. S. D. Anton, C. K. Martin, H. Han, S. Coulon, W. T. Cefalu, P. Geiselman and D. A. Williamson, Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels, *Appetite*, 2010, **55**, 37-43.
9. N. S. Stamatakis, S. McKie, C. Scott, D. Bosscher, R. Elliott and J. T. McLaughlin, Mapping the Homeostatic and Hedonic Brain Responses to Stevia Compared to Caloric Sweeteners and Water: A Double-Blind Randomised Controlled Crossover Trial in Healthy Adults, *Nutrients*, 2022, **14**.
10. A. W. R. Ng, K. K. Loh, N. Gupta and K. Narayanan, A polyol-stevia blended

- sugar replacer exhibits low glycemic response among human subjects, *Clin. Nutr. ESPEN*, 2019, **33**, 39-41.
11. N. S. Stamataki, C. Scott, R. Elliott, S. McKie, D. Bosscher and J. T. McLaughlin, Stevia Beverage Consumption prior to Lunch Reduces Appetite and Total Energy Intake without Affecting Glycemia or Attentional Bias to Food Cues: A Double-Blind Randomized Controlled Trial in Healthy Adults, *J. Nutr.*, 2020, **150**, 1126-1134.
  12. B. Oliveira, K. Falkenhain and J. P. Little, Sugar-Free Dark Chocolate Consumption Results in Lower Blood Glucose in Adults With Diabetes, *Nutr. Metab. Insights.*, 2022, **15**, 11786388221076962.
  13. N. R. Mayasari, Susetyowati, M. S. H. Wahyuningsih and Probosuseno, Antidiabetic Effect of Rosella-Stevia Tea on Prediabetic Women in Yogyakarta, Indonesia, *J. Am. Coll. Nutr.*, 2018, **37**, 373-379.
  14. N. Hazali, A. Mohamed, M. Ibrahim, M. Masri, K. A. M. Isa, N. M. Nor, M. K. Ayob and F. N. M. Fadzlan, Effect of Acute Stevia Consumption on Blood Glucose Response in Healthy Malay Young Adults, *Sains Malays.*, 2014, **43**, 649-654.
  15. O. Pjanykh, A. Ametov, A. Vaynshtock, V. Popov, N. Bulanova and C. Tyranovetz, Effect of specialized confectionary products '0 calories' intake on glucose level in diabetic patients, *Int. J. Hypertens.*, 2019, **37**, e163.
  16. A. K. Obidul Huq, K. M. Formuzul Haque and H. N. M. Ekramul Mahmud, Formulation of anti-diabetic herbal tea from basil leaves, *Arch. Pharm. Res.*, 2014, **5**, S2.
  17. P. Van den Abbeele, J. Poppe, S. Deyaert, I. Laurie, T. K. Otto Gravert, A. Abrahamsson, A. Baudot, K. Karnik and D. Risso, Low-no-calorie sweeteners exert marked compound-specific impact on the human gut microbiota ex vivo, *Int. J. Food Sci. Nutr.*, 2023, **74**, 630-644.
  18. J. M. Geuns, J. Buyse, A. Vankeirsbilck and E. H. Temme, Metabolism of stevioside by healthy subjects, *Exp. Biol. Med. (Maywood)*, 2007, **232**, 164-173.
  19. J. Suez, Y. Cohen, R. Valdes-Mas, U. Mor, M. Dori-Bachash, S. Federici, N. Zmora, A. Leshem, M. Heinemann, R. Linevsky, M. Zur, R. B. Brik, A. Bukimer, S. Eliyahu-Miller, A. Metz, R. Fischbein, O. Sharov, S. Malitsky, M. Itkin, N. Stettner, A. Harmelin, H. Shapiro, C. K. Stein-Thoeringer, E. Segal

- and E. Elinav, Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance, *Cell*, 2022, **185**, 3307-+.
20. S. Bastaki, Pharmacotherapy of nonnutritive sweeteners in diabetes mellitus, *J. Diabetes Metab. Disord.*, 2015, **23**, 11-12.
  21. T. P. Dooley, J. M. P. Pérez and C. R. Rodriquez, Stevia and Uncaria extract (GlucoMedix®) reduces glucose levels and the need for medications in type 2 diabetes: an open label case series of six patients, *Clin. Phytoscience*, 2022, **8**.
  22. G. Raghavan, A. Bapna, A. Mehta, A. Shah and T. Vyas, Effect of Sugar Replacement with Stevia-Based Tabletop Sweetener on Weight and Cardiometabolic Health among Indian Adults, *Nutrients*, 2023, **15**.
  23. E. Almiron-Roig, S. Navas-Carretero, G. Castelnuovo, L. Kjolbaek, A. Romo-Hualde, M. Normand, N. Maloney, C. A. Hardman, C. E. Hodgkins, H. Moshoyannis, G. Finlayson, C. Scott, M. M. Raats, J. A. Harrold, A. Raben, J. C. G. Halford and J. A. Martinez, Impact of acute consumption of beverages containing plant-based or alternative sweetener blends on postprandial appetite, food intake, metabolism, and gastro-intestinal symptoms: Results of the SWEET beverages trial, *Appetite*, 2023, **184**.
  24. N. N. É. Camille, D. L. Emili Marcelle Adjelle, E. N. Nga, C. N. Nganou-Gnindjio, E. Sobngwi and N. N. É. Camille, Short-term effects of a standardized beverage from aqueous extracts of hibiscus sabdariffa and stevia rebaudiana on diastolic function and circadian blood pressure of cameroonians with type 2 diabetes patients, *Int. J. Hypertens.*, 2018, **36**, e231.
  25. C. Nganou-Gnindjio, L. Mfeukeu Kuaté, E. C. Noubissi Nouno, A. Tankeu T, L. Ngah Mvogo, D. Ngati Nyonga, E. Nnanga Nga and E. Sobngwi, Short-term effects of a standardized beverage from aqueous extracts of Hibiscus sabdariffa and Stevia rebaudiana on diastolic function of Cameroonians with type 2 diabetes, *Arch. Cardiovas. Dis.*, 2019, **11**, 154-155.
  26. T. Horio, Effect of physical exercise on human preference for solutions of various sweet substances, *Percept. Mot. Skills*, 2004, **99**, 1061-1070.
  27. A. Kochhar, S. Dhindsa and R. Sachdeva, Effect of Stevia Leaf (Stevia rebaudiana) Powder Supplementation and Nutrition Counselling on Anthropometric Parameters and Gain in Knowledge of the Subjects, *Studies on Ethno-Medicine*, 2008, **2**, 107-113.
  28. M. Taghizadeh and Z. Asemi, Effects of synbiotic food consumption on

- glycemic status and serum hs-CRP in pregnant women: a randomized controlled clinical trial, *HORM-INT J. Endocrinol.*, 2014, **13**, 398-406.
29. Z. Asemi, A. Khorrami-Rad, S.-A. Alizadeh, H. Shakeri and A. Esmaillzadeh, Effects of synbiotic food consumption on metabolic status of diabetic patients: A double-blind randomized cross-over controlled clinical trial, *Clin. Nutr.*, 2014, **33**, 198-203.
30. L. Melo, J. L. Childs, M. Drake, H. M. Andre Bolini and P. Efraim, EXPECTATIONS AND ACCEPTABILITY OF DIABETIC AND REDUCED-CALORIE MILK CHOCOLATES AMONG NONDIABETICS AND DIABETICS IN THE USA, *J. Sens. Stud.*, 2010, **25**, 133-152.
31. M. van Avesaat, F. J. Troost, D. Ripken, J. Peters, H. F. Hendriks and A. A. Masclee, Intraduodenal infusion of a combination of tastants decreases food intake in humans, *Am. J. Clin. Nutr.*, 2015, **102**, 729-735.
32. E. Kassi, G. Landis, A. Pavlaki, G. Lambrou, E. Mantzou, I. Androulakis, A. Giannakou, E. Papanikolaou and G. P. Chrousos, Acute effects of stevia rebaudiana extract on postprandial glucose metabolism in patients with metabolic syndrome, *Endocr. Rev.*, 2016, **37**.
33. S. Gregersen, K. Hermansen, P. B. Jeppesen and J. J. Holst, Acute effects of the diterpene glycoside Steviosede in type II diabetic patients, *Diabetologia*, 2001, **44**, A236-A236.
34. C. Scott, F. Au-Yeung, N. Strom, T. Wolever, A. Chakrabarti, D. Kwok, C. Lam and T. Hutton, Comparison of a Daily Stevia Beverage vs. a Sucrose Sweetened Beverage on the Human Gut Microbiome, Cardiometabolic Functions and Anthropometric Measurements, *Curr. Dev. Nutr.*, 2023, **7**.
35. K. Aguilar, P. Medina, A. Miranda, M. Klunder, B. Lopez and A. Vilchis, Effects of Cola Drinks and Nonnutritive with Nutritive Sweeteners on Glucose and Pancreatic Response. Crossover Trial in with Adolescents Obesity, Type 2 Diabetes and Eutrophics, *Horm. Res. Paediat.*, 2018, **90**, 9-9.
36. R. M. Pereira, M. Secaf and R. B. de Oliveira, Effects of different sweeteners on incretin hormone secretion, gastric emptying, intragastric distribution and postprandial glycemia in healthy humans, *FASEB J.*, 2013, **27**.
37. P. B. Jeppesen, L. Barriocanal, M. T. Meyer, M. Palacios, F. Canete, S. Benitez, S. Logwin, Y. Schupmann, G. Benitez and J. T. Jimenez, Efficacy and tolerability of oral stevioside in patients with type 2 diabetes: a long-term,

- randomized, double-blinded, placebo-controlled study, *Diabetologia*, 2006, **49**, 511-512.
38. K. C. Maki, L. L. Curry, J. M. McKenney, M. V. Farmer, M. S. Reeves, M. R. Dicklin, J. E. Gerich and B. Zinman, Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus, *FASEB J.*, 2009, **23**.
  39. S. J. Jeong and J. H. Kim, Glycemic effect of sweetener, sweete GI-0 in peoples with glucose intolerance, *Endocr. Rev.*, 2014, **35**.
  40. G. G. Roch, G. N. S. Canchaya, E. F. Juarez, J. M. F. Luna, G. A. G. Brizuela and L. K. H. Calderon, Influence of Magnesium Chloride with Stevia on Glucose Biochemistry in Patients with Type 2 Diabetes, *Ann. Nutr. Metab.*, 2023, **79**.
  41. G. Farhat, L. Moore, I. Moya, L. Hall and V. Berset, An Investigation into the Effects of Stevia on food intake, satiety and blood glucose levels in adults: a small-scale study, *Proc. Nutr. Soc.*, 2020, **79**, E171-E171.
  42. E. N. Kassi, G. Landis, A. Pavlaki, G. Lambrou, E. Mantzou, I. Androulakis, A. Giannakou, E. Papanikolaou and G. P. Chrousos, Long-term effects of stevia rebaudiana on glucose and lipid profile, adipocytokines, markers of inflammation and oxidation status in patients with metabolic syndrome, *Endocr. Rev.*, 2016, **37**.
  43. F. Rizwan, H. U. Rashid, S. Yesmine, F. Monjur and T. K. Chatterjee, POS-393 POTENTIAL BENEFICIAL EFFECTS OF STEVIOSIDE IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS (STAGE-I TO STAGE-III): A PROSPECTIVE CLINICAL TRIAL IN A TERTIARY HOSPITAL IN BANGLADESH, *Kidney Int. Rep.*, 2022, **7**, S177-S178.
  44. S. P. Sanja, D. Lalosevic, I. Capo and T. M. Popin, Protective effect of Stevioside, Roziglitazon and preparations based on barley and barm at artificially induced diabetes mellitus by Alloxan, *Cardiovasc. Res.*, 2010, **87**, S66-S66.
  45. N. N. E. Camille, E. M. D. L. Adjelle, E. N. Nga, C. N. Nganou-Gnindjio, E. Sobngwi and N. N. Emile Camille, SHORT-TERM EFFECTS OF A STANDARDIZED BEVERAGE FROM AQUEOUS EXTRACTS OF HIBISCUS SABDARIFFA AND STEVIA REBAUDIANA ON DIASTOLIC FUNCTION AND CIRCADIAN BLOOD PRESSURE OF

- CAMEROONIANS WITH TYPE 2 DIABETES PATIENTS, *Int. J. Hypertens.*, 2018, **36**, E231-E231.
46. E. M. Timpe Behnen, M. C. Ferguson and A. Carlson, Do sugar substitutes have any impact on glycemic control in patients with diabetes?, *J. Pharm. Technol.*, 2013, **29**, 61-65.